Patents by Inventor Harpreet Singh

Harpreet Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
    Patent number: 11826409
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: November 28, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
  • Peptides and combination of peptides for use in immunotherapy against various cancers
    Patent number: 11826410
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: November 28, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • HARDWARE TO UNIFORMLY DISTRIBUTE ACTIVE SPECIES FOR SEMICONDUCTOR FILM PROCESSING
    Publication number: 20230374660
    Abstract: A substrate processing system is provided having a processing chamber. The processing chamber includes a lid plate, one or more chamber sidewalls, and a chamber base that collectively define a processing volume. An annular plate is coupled to the lid plate, and an edge manifold is fluidly coupled to the processing chamber through the annular plate and the lid plate. The substrate processing system includes a center manifold that is coupled to the lid plate.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 23, 2023
    Inventors: Harpreet SINGH, Jallepally RAVI, Zubin HUANG, Manjunatha KOPPA, Sandesh YADAMANE, Srinivas TOKUR MOHANA, Shreyas PATIL SHANTHAVEERASWAMY, Kai WU, Peiqi WANG, Mingrui ZHAO
  • Immunotherapy against several tumors including lung cancer
    Patent number: 11814446
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: November 14, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • METHOD AND SYSTEM FOR CLOUD DESKTOP FABRIC
    Publication number: 20230359474
    Abstract: A system and method for a virtual desktop system is disclosed. The system includes a master fabric region including resources for provisioning a desktop. The system includes an expansion fabric region including replicated resources for provisioning the desktop from the master fabric region. The system includes a control plane having a global pool. A client device application operated by a user associated with the global pool accesses a desktop from either the master fabric region or the expansion fabric region.
    Type: Application
    Filed: June 5, 2023
    Publication date: November 9, 2023
    Inventors: David T. Sulcer, Shiva Prasad Madishetti, Lisa Wing San Chui, Anushree Kunal Pole, Joseph V. Semmelrock, SR., Virabrahma Prasad Krothapalli, Amitabh Bhuvangyan Sinha, Jimmy Chang, Harpreet Singh Labana, Raminder S. Channe
  • NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
    Publication number: 20230348563
    Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.
    Type: Application
    Filed: May 10, 2023
    Publication date: November 2, 2023
    Inventors: Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH, Lea STEVERMANN
  • NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
    Publication number: 20230340046
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 10, 2023
    Publication date: October 26, 2023
    Inventors: Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS
    Publication number: 20230338489
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 25, 2023
    Publication date: October 26, 2023
    Inventors: Andrea MAHR, Toni WEINSCHENK, Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Peptides and T cells for use in immunotherapeutic treatment of various cancers
    Patent number: 11793866
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: October 24, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
    Publication number: 20230331807
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 9, 2023
    Publication date: October 19, 2023
    Inventors: Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH, Gisela SCHIMMACK, Michael ROEMER
  • Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
    Patent number: 11786584
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor associated T-cell peptide epitopes, alone or in combination with other tumor associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: October 17, 2023
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
  • System and method for tracing nets across multiple fabrics in an electronic design
    Patent number: 11790149
    Abstract: Embodiments include herein are directed towards a method for electronic circuit design is provided. Embodiments may include allowing, at a graphical user interface, a user to initiate a co-design mode associated with an electronic design. Embodiments may further include allowing, at the GUI, the user to select a shape to trace connectivity from. Embodiments may also include tracing the connectivity of the shape across one or more overlaps and identifying one or more pins associated with the connectivity. Embodiments may further include determining a correct pin from an instance associated with the connectivity and displaying the connectivity at the GUI.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: October 17, 2023
    Assignee: Cadence Design Systems, Inc.
    Inventors: Devendra Ramakant Deshpande, Arnold Jean Marie Gustave Ginetti, Fabien Campana, Harpreet Singh, Tapan Kumar Singh
  • Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods
    Patent number: 11779605
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: October 10, 2023
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Gisela Schimmack, Annika Sonntag, Heiko Schuster, Daniel Johannes Kowalewski, Michael Roemer, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Harpreet Singh
  • NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS
    Publication number: 20230312679
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: January 13, 2023
    Publication date: October 5, 2023
    Inventors: Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Building management system with device twinning, communication connection validation, and block chain
    Patent number: 11774925
    Abstract: A building management system includes one or more processing circuits. The one or more processing circuits are configured to receive, from a physical building device of a building, environmental inputs and environmental outputs of the physical building device; generate a building device digital twin for the physical building device based on the received environmental inputs and the received environmental outputs; generate a predicted future performance of the physical building device based on the building device digital twin; and generate a recommendation based on the predicted future performance of the physical building device, the recommendation indicating one or more changes to implement on the physical building device. The building device digital twin is a model for predicting the behavior of the physical building device ore changes to implement on the physical building device.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: October 3, 2023
    Assignee: JOHNSON CONTROLS TYCO IP HOLDINGS LLP
    Inventors: Vikas Sharma, Sudhanshu Dixit, Ankur Thareja, Rajesh Nayak, Harpreet Singh Virdi, Anil Kumar, Rajeev T. Singh
  • Personalized immunotherapy against several neuronal and brain tumors
    Patent number: 11759507
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: September 19, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Sabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh
  • B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
    Publication number: 20230287071
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: March 24, 2023
    Publication date: September 14, 2023
    Inventors: Colette SONG, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
    Publication number: 20230287069
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: August 12, 2022
    Publication date: September 14, 2023
    Inventors: Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
    Publication number: 20230279066
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 7, 2023
    Publication date: September 7, 2023
    Inventors: Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • Shadow ring lift plate
    Patent number: D997893
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: September 5, 2023
    Assignee: APPLIED MATERIALS, INC.
    Inventors: Zubin Huang, Srinivas Tokur Mohana, Shreyas Patil Shanthaveeraswamy, Sandesh Yadamane, Jallepally Ravi, Harpreet Singh, Manjunatha Koppa